134 related articles for article (PubMed ID: 17622180)
21. Chymase and matrix metalloproteinase.
Urata H
Hypertens Res; 2007 Jan; 30(1):3-4. PubMed ID: 17460365
[No Abstract] [Full Text] [Related]
22. Matrix metalloproteinase inhibitors: specificity of binding and structure-activity relationships.
Gupta SP
Exp Suppl; 2012; 103():v-vi. PubMed ID: 22642187
[No Abstract] [Full Text] [Related]
23. Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.
Li Q; Fang H; Xu W
Bioorg Med Chem Lett; 2007 May; 17(10):2935-8. PubMed ID: 17433673
[TBL] [Abstract][Full Text] [Related]
24. A high-affinity carbohydrate-containing inhibitor of matrix metalloproteinases.
Calderone V; Fragai M; Luchinat C; Nativi C; Richichi B; Roelens S
ChemMedChem; 2006 Jun; 1(6):598-601. PubMed ID: 16892399
[No Abstract] [Full Text] [Related]
25. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).
Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583
[TBL] [Abstract][Full Text] [Related]
26. Insight into the structural determinants for selective inhibition of matrix metalloproteinases.
Pirard B
Drug Discov Today; 2007 Aug; 12(15-16):640-6. PubMed ID: 17706545
[TBL] [Abstract][Full Text] [Related]
27. Design in silico, synthesis and binding evaluation of a carbohydrate-based scaffold for structurally novel inhibitors of matrix metalloproteinases.
Fragai M; Nativi C; Richichi B; Venturi C
Chembiochem; 2005 Aug; 6(8):1345-9. PubMed ID: 15977273
[No Abstract] [Full Text] [Related]
28. Biological activity and clinical implications of the matrix metalloproteinases.
Rydlova M; Holubec L; Ludvikova M; Kalfert D; Franekova J; Povysil C; Ludvikova M
Anticancer Res; 2008; 28(2B):1389-97. PubMed ID: 18505085
[TBL] [Abstract][Full Text] [Related]
29. High-resolution crystal structure of the snake venom metalloproteinase BaP1 complexed with a peptidomimetic: insight into inhibitor binding.
Lingott T; Schleberger C; Gutiérrez JM; Merfort I
Biochemistry; 2009 Jul; 48(26):6166-74. PubMed ID: 19485419
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase proteomics: substrates, targets, and therapy.
Morrison CJ; Butler GS; Rodríguez D; Overall CM
Curr Opin Cell Biol; 2009 Oct; 21(5):645-53. PubMed ID: 19616423
[TBL] [Abstract][Full Text] [Related]
31. [Bisphosphonates inhibit matrix metalloproteinases--a new possible mechanism of action].
Teronen O; Konttinen YT; Salo T; Lindqvist C; Heikkilä P; Laitinen M; Sorsa T
Duodecim; 1999; 115(1):13-5. PubMed ID: 11830856
[No Abstract] [Full Text] [Related]
32. Synthesis and evaluation of novel oxazoline MMP inhibitors.
Cook GR; Manivannan E; Underdahl T; Lukacova V; Zhang Y; Balaz S
Bioorg Med Chem Lett; 2004 Oct; 14(19):4935-9. PubMed ID: 15341955
[TBL] [Abstract][Full Text] [Related]
33. Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups.
Nicolotti O; Miscioscia TF; Leonetti F; Muncipinto G; Carotti A
J Chem Inf Model; 2007; 47(6):2439-48. PubMed ID: 17958346
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinases.
Fridman R
Biochim Biophys Acta; 2010 Jan; 1803(1):1-2. PubMed ID: 20159302
[No Abstract] [Full Text] [Related]
35. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue.
Waddell DD; Kolomytkin OV; Dunn S; Marino AA
Clin Orthop Relat Res; 2007 Dec; 465():241-8. PubMed ID: 18090474
[TBL] [Abstract][Full Text] [Related]
36. Making a new turn in matrix metalloprotease inhibition.
Wasserman ZR
Chem Biol; 2005 Feb; 12(2):143-4. PubMed ID: 15734640
[TBL] [Abstract][Full Text] [Related]
37. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors.
Nuti E; Tuccinardi T; Rossello A
Curr Pharm Des; 2007; 13(20):2087-100. PubMed ID: 17627541
[TBL] [Abstract][Full Text] [Related]
38. Role of proteolysis in development of murine adipose tissue.
Christiaens V; Scroyen I; Lijnen HR
Thromb Haemost; 2008 Feb; 99(2):290-4. PubMed ID: 18278177
[TBL] [Abstract][Full Text] [Related]
39. Enzymatic activation of a matrix metalloproteinase inhibitor.
Major Jourden JL; Cohen SM
Chem Commun (Camb); 2010 Feb; 46(8):1241-3. PubMed ID: 20449263
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Eur J Med Chem; 2008 Oct; 43(10):2130-9. PubMed ID: 18362041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
